Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
about
PTPN14 is required for the density-dependent control of YAP1Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactionsInteraction proteome of human Hippo signaling: modular control of the co-activator YAP1PTPN14 interacts with and negatively regulates the oncogenic function of YAPStructures of YAP protein domains reveal promising targets for development of new cancer drugsα-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1Mechanoregulation of Wound Healing and Skin HomeostasisYAP-Mediated Mechanotransduction in Skeletal MuscleEmerging role of Hippo pathway in gastric and other gastrointestinal cancersCadherin signaling: keeping cells in touchMST kinases in development and diseaseEvasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.Mammalian Hippo signalling: a kinase network regulated by protein-protein interactionsHarnessing Hippo in the heart: Hippo/Yap signaling and applications to heart regeneration and rejuvenationThe two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatmentFunctional role of Mst1/Mst2 in embryonic stem cell differentiationAtypical protein kinase C induces cell transformation by disrupting Hippo/Yap signaling.FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature.Constitutive expression of Yes-associated protein (Yap) in adult skeletal muscle fibres induces muscle atrophy and myopathyTargeting Mechanotransduction at the Transcriptional Level: YAP and BRD4 Are Novel Therapeutic Targets for the Reversal of Liver FibrosisTargeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer TherapyYAP and TAZ: a nexus for Hippo signaling and beyondEmerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancerOpposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAPTumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivatorsRegulation of localization and function of the transcriptional co-activator YAP by angiomotin.Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.The Hippo-YAP signaling pathway and contact inhibition of growth.The Hippo signaling pathway in stem cell biology and cancerRegulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1What do mechanotransduction, Hippo, Wnt, and TGFβ have in common? YAP and TAZ as key orchestrating molecules in ocular health and disease.Angiomotins link F-actin architecture to Hippo pathway signaling.Crumbs promotes expanded recognition and degradation by the SCF(Slimb/β-TrCP) ubiquitin ligaseHippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.Angiomotin Family Members: Oncogenes or Tumor Suppressors?Age-related dysfunction in mechanotransduction impairs differentiation of human mammary epithelial progenitorsPP1A-mediated dephosphorylation positively regulates YAP2 activityZO proteins redundantly regulate the transcription factor DbpA/ZONABDown-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells.Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP.
P2860
Q24297998-D11B010C-A7F2-4D5B-AC1B-E9CFD8F71059Q24307997-E6C0E916-610E-4483-9690-F54CBA4C9F42Q24316087-50F8255E-C603-40F0-A9F1-C87B2128D63EQ24316475-1556C801-F384-4472-AA5D-E93B817D2842Q24612471-52C088E1-65FA-497D-85E2-FBFA49B0F97EQ24613385-C82DBB1F-FA25-4F54-BBDE-13C746ACDE01Q26740308-5C7033F7-D93A-4260-88FF-A19A8A1E7071Q26766774-5A3BDD8A-6661-4581-A7AE-C63CDC66A17AQ26774473-247830BF-BD85-43EF-AC44-2052D2B2EC95Q26784615-CD9523DB-43BB-47F1-99ED-987AA466CCCAQ26787040-5B36E7A0-4085-4ED1-9236-0640C6189DD6Q26827810-CCAD1B0D-DAD6-4FA3-97C8-F24582BD0A0AQ26849472-B2F5D508-5EFD-4BC7-8ED2-65C1F1F0CA90Q26995264-62A4955D-6495-4698-AFFF-ACA97A7E755BQ27025661-28F970E1-0DBD-484C-B226-6C8AF11DD2FCQ27302367-10152C15-9F35-4A25-8BC0-6F62E7D566D0Q27305890-6F0FECAD-D566-44F7-A5DB-846ABB8C4394Q27332286-1758ED9D-56F4-4C05-878A-AD3BE92BBBE6Q27333208-B45E2A79-190F-46D3-B4DE-6A56BBE2731FQ28070012-DBCDFEEB-FAAD-4817-A2A2-49CC4E5B65EAQ28078129-F12542FD-5055-4ED0-B279-BE18318DD9A3Q28085636-E0C509E6-BBA0-44D8-9771-FA6DF45AE9E1Q28086905-24359D8A-B533-4842-8744-EC4CDBCEAE5CQ28241192-3546F33F-3CF9-4B69-BB2D-47338B0B78DBQ28504464-BA49A751-705C-43C8-9CED-3F7FCF605572Q30352874-4CD9B622-490F-4FDA-AE26-2339F8BD3704Q30354662-B0726549-41E5-473A-8F87-404B3E4AEADCQ30408095-C3B282B8-DEC5-44D3-8324-CC9EF9BFA9EFQ30410176-77CF46BF-C414-4500-8085-E86B34A35ED3Q30417692-AFF3F2C1-05BE-4D48-AFF2-C02A92F87B63Q30429628-70C22043-526B-4C97-8225-B9D1616BD7FFQ33604410-F3162BFB-78AE-40D0-BF1F-FB81D4F651DDQ33627336-CD8D77F2-5E3C-4FEF-9E5F-CD2F1F0E0299Q33819083-E89A8DCA-C500-4D62-AB95-BC2F0F6F8698Q33837277-CCE5FBDD-5E46-4771-BF12-07CF20C19BB3Q34004237-1E7E0B1C-4FA9-459A-9F9B-8BCF82651482Q34016621-313C2747-86E5-406D-BD19-E92C81B7EDF6Q34070506-CCF290E9-DA76-4DD0-A2F0-CB2F90BFBD3DQ34187277-D23D8606-DC4A-4F35-BD9B-08431A1479E2Q34191953-750EDEF1-64B5-4314-B6F5-619A3A36913E
P2860
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@ast
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@en
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@en-gb
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@nl
type
label
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@ast
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@en
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@en-gb
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@nl
prefLabel
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@ast
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@en
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@en-gb
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@nl
P2093
P2860
P3181
P356
P1433
P1476
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
@en
P2093
Chen-Ying Liu
Kun-Liang Guan
Lloyd H Wang
Qunying Lei
P2860
P3181
P356
10.1101/GAD.2000111
P407
P577
2011-01-01T00:00:00Z